Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report
Internal Medicine Journal · 2025
DOI: 10.1111/imj.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Arina Martynchyk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Registries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: BeiGene.
Abstract (Originalsprache)
Background
Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real‐world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited.
Aims
Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR).
Methods
This study included 365 patients aged ≥18 years with CLL diagnosed between January 2016 and May 2023.
Results
Median age at diagnosis was 68 years, with 65% being male. Median follow‐up was 15.2 months (range 0–78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow‐up, 38% of patients commenced first‐line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B‐cell lymphoma 2 inhibitors increased more than 10‐fold following regulatory approval in 2020. Two‐year progression‐free and overall survival, measured from commencement of first‐line therapy, were 67% (95% CI 55–76) and 87% (95% CI 78–93) respectively.
Conclusion
The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Department of Haematology, Monash Health, Melbourne, Victoria, Australia.
- Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
ORCID-Profile: Arina Martynchyk, Erica M Wood, Eliza A Hawkes
Förderung
- BeiGene
Zitieren
APA
Martynchyk, A., Wellard, C., Chung, E., Bhopal, S. K., McQuilten, Z. K., Mulligan, S. P., Opat, S., Wood, E. M., Hawkes, E. A., & Anderson, M. A. (2025). Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report. Internal Medicine Journal. https://doi.org/10.1111/imj.70037
Vancouver
Martynchyk A, Wellard C, Chung E, Bhopal SK, McQuilten ZK, Mulligan SP, et al. Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report. Internal Medicine Journal. 2025. doi:10.1111/imj.70037
BibTeX
@article{Martynchyk2025,
author = {Martynchyk, Arina and Wellard, Cameron and Chung, Eliza and Bhopal, Simran K and McQuilten, Zoe K and Mulligan, Stephen P and Opat, Stephen and Wood, Erica M and Hawkes, Eliza A and Anderson, Mary A},
title = {Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.70037}
}
EUVIMED